Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QX004N in Moderate to Severe Plaque Psoriasis
ChiCTR2300075645Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX004N in plaque psoriasis (4 arms), sponsored by Peking University People's Hospital. Primary endpoint: Proportion of subjects achieving PASI90. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
QX004N
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on ChiCTR2300075645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075645.